कंपनी का अवलोकन
Annexon, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to discovering and developing therapeutic medicines specifically designed to treat inflammatory-related diseases. The company focuses its research and development efforts on Tanruprubart, which is an investigational full-length monoclonal antibody currently progressing through Phase 3 clinical trials for the treatment of patients with Guillain-Barre syndrome. This organization functions within the broader Healthcare sector and more specifically within the Biotechnology industry, a classification that indicates a focus on biological agents rather than small molecule drugs. In terms of scale, Annexon, Inc. maintains a market capitalization of $985.31M and employs a workforce of 96 individuals. The market cap figure suggests that the company holds a mid-cap valuation typical for specialized biotechnology firms that are still in the clinical development phase, while the revenue metric is not publicly disclosed in the current reporting period. The combination of a substantial cash position and a relatively small employee base highlights a capital-intensive business model where significant financial resources are required to advance clinical candidates before generating commercial sales revenue.
वित्तीय स्वास्थ्य
The company reported a net income of $-208,547,008 over the trailing twelve-month period, while its EBITDA stands at $-214,240,992. The absence of reported revenue figures alongside these significant net losses reveals a cost structure dominated by research, development, and clinical trial expenses rather than commercial operating costs. Free cash flow for the period was recorded at $-104,476,376, which indicates that the company is consuming cash to fund its operations and clinical programs rather than generating liquidity from sales. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, reflecting the current stage of development where no commercial revenue is being recognized to cover the substantial overhead and R&D expenditures. On the balance sheet, the company holds $238.34M in cash against $26.20M in total debt, resulting in a debt-to-equity ratio of 12.38. Despite the high leverage ratio on paper, the substantial cash reserves relative to debt suggest a conservative liquidity posture regarding immediate solvency, though the debt figure must be managed carefully as clinical milestones are met. The current ratio is 5.68, which indicates a robust short-term liquidity position where current assets significantly exceed current liabilities. Return on Equity is -81.9% and Return on Assets is -43.1%, metrics that reveal management is currently deploying capital to generate losses in pursuit of future product approvals rather than delivering immediate profitability to shareholders.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to the absence of earnings, while the forward P/E is -6.42, a negative figure that implies the market is pricing in future earnings recovery rather than current profitability. The price-to-book ratio stands at 4.33, indicating that the stock trades at a significant premium over its book value, a common characteristic for biotechnology companies where intangible assets and intellectual property drive valuation rather than tangible net worth. The price-to-sales ratio is N/A and the EV/EBITDA is -3.61; these alternative metrics suggest that traditional valuation multiples are not applicable, and investors are relying on pipeline potential and cash runway instead. The 52-week high is $7.18 and the 52-week low is $1.28, placing the current valuation context within a wide trading range that reflects high volatility associated with clinical-stage assets. With a beta of 1.15, the stock exhibits price volatility that is slightly higher than the broader market, indicating that price movements are amplified by sector-specific news regarding clinical trial results or regulatory decisions.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both reported as N/A, as the company has not yet achieved commercial product launches to establish a historical growth trajectory. Consequently, it is not possible to compare earnings growth against revenue growth at this stage, as the primary focus remains on advancing the Tanruprubart candidate through clinical trials rather than expanding sales volume. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings and cash flows are retained within the business to fund ongoing research and development activities. This reinvestment strategy is typical for clinical-stage biopharmaceuticals, where capital is directed toward achieving clinical milestones and regulatory approval rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current commercial revenue or dividend income, relying entirely on the successful commercialization of its investigational drug candidates to transform its financial status in the future.